Loading...
Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer.
Hiew, Kenneth Hart, Claire A Ali, Adnan Ramani, Vijay A C Sangar, Vijay K Lau, Maurice W Maddineni, Satish B Brown, Michael D
Hiew, Kenneth
Hart, Claire A
Ali, Adnan
Ramani, Vijay A C
Sangar, Vijay K
Lau, Maurice W
Maddineni, Satish B
Brown, Michael D
Citations
Altmetric:
Abstract
Docetaxel chemotherapy is a standard of care for metastatic castrate-resistant prostate cancer (mCRPC): 40-50% of patients achieve a biochemical response. However, there is a lack of response predictive biomarkers.
Description
Date
2018-04-23
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 2.05 MB
Keywords
Type
Article
Citation
Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer. 2018, Eur Urol Focus